Strand Doses First Patient With STX-001 mRNA Therapy In Phase 1
30 May 2024 //
BUSINESSWIRE
Exclusive: Strand lays off 18% of staff
26 Jan 2024 //
ENDPTS
Strand Receives IND Clearance for Programmable mRNA Therapy STX-001
22 Jan 2024 //
BUSINESSWIRE
Strand Therapeutics Appoints Colleen Wilson as Chief People Officer
24 Apr 2023 //
BUSINESSWIRE
Strand Presents Preclinical Data Programmable mRNA Therapy STX-001 at AACR 2023
17 Apr 2023 //
BUSINESSWIRE
Strand Announces Poster Presentation on STX-001 at the 2023 AACR Annual Meeting
14 Mar 2023 //
BUSINESSWIRE
Strand Therapeutics Appoints Jay Stella as Chief Business Officer
01 Mar 2023 //
BUSINESSWIRE
Strand Therapeutics raises millions to test targeted cancer therapies
29 Nov 2022 //
STATNEWS
Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million
28 Nov 2022 //
BUSINESSWIRE
Strand Tx Appoints Dr. Prashant Nambiar as Senior VP, R&TD
08 Feb 2022 //
BUSINESSWIRE
Strand Awarded Phase I NIH SBIR Contract for mRNA-based CAR-T Immunotherapy
09 Nov 2021 //
BUSINESSWIRE
Biogen, Mirati, mRNA players on Merck`s M&A shortlist: FT
06 Oct 2021 //
FIERCEPHARMA
Strand Therapeutics Awarded Two Phase I NIH SBIR Grants
04 Aug 2021 //
BUSINESSWIRE
Strand Therapeutics’ Jake Becraft Named an MIT Technology Review 2021
30 Jun 2021 //
BUSINESSWIRE
Strand Therapeutics Raises $52M in Oversubscribed Series A Round
23 Jun 2021 //
BUSINESSWIRE